4 recruiting. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 4 |
| Phase 1 | 1 | Recruiting 1 |
Follow Blast Crisis: new trials by email Literature Review of Blast Crisis trials Research Report on Blast Crisis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Ponatinib - Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | Incyte Biosciences International Sàrl | 70 | 2020-01-29 | 2026-10-09 |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers Cladribine, Cytarabine, Dexrazoxane Hydrochloride - Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 100 | 2018-09-19 | 2026-05-22 |
| Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia Blinatumomab, Cytarabine, Methotrexate - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 90 | 2017-11-29 | 2026-05-20 |
| Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia Cladribine, Cytarabine, Gilteritinib - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 508 | 2014-05-19 | 2026-05-20 |
Leukemia, Myeloid, Acute (3) · Leukemia, Myeloid, Accelerated Phase (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Leukemia (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Chronic-Phase (1) · Lymphoma (1) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1) · Sarcoma, Myeloid (1)
Bone Marrow Diseases (4) · Carcinogenesis (4) · Cell Transformation, Neoplastic (4) · Chronic Disease (4) · Disease Attributes (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Leukemia, Myeloid (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplastic Processes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Immune System Diseases (3) · Immunoproliferative Disorders (3)
Cytarabine (3) · Cladribine (2) · Idarubicin (2) · ponatinib (2) · Dexrazoxane (1) · Gemtuzumab (1) · Methotrexate (1) · N,N-dicyclohexyl-isoborneol-10-sulfonamide (1) · Razoxane (1) · blinatumomab (1) · gilteritinib (1) · merphos (1) · midostaurin (1) · venetoclax (1)
M.D. Anderson Cancer Center (3) · Incyte Biosciences International Sàrl (1)
United States (3) · Belgium (1) · France (1) · Italy (1) · Netherlands (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Elias Jabbour (1) · Maro Ohanian (1) · Mohammed-El-Amine Bensmaine, MD (1) · Tapan M Kadia (1)
PMID 29702001, PMID 34329576, PMID 36402146, PMID 39028925, PMID 40193193, PMID 40369607, PMID 40500616
2018 (1), 2023 (1), P30CA016672 (1)